| DB ID | MyCo_3306 |
| Title | Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis |
| Year | 2022 |
| PMID | 35652817 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | stem cell transplant recipients and acute leukemia patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-6 |
| Biomarker Full Name | Interleukin-6 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | We performed a prospective, multicenter matched case- control study of all hospitalized patients with acute leukemia (AL)and/orallogenichematopoieticstemcelltransplantation (HSCT) recipients from four tertiary teaching institutions in Spain. The study period took place between January 2011 and December 2014. We included 36 patients with IA and 36 controls. |
| Cohort No. | 36 Patients and 36 control |
| Age Group | 47–66.8 |
| P Value | p=0.001 |
| Sensitivity | 0.722 |
| Specificity | 0.778 |
| Positive Predictive Value | 0.765 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is a life-threatening disease that affects severely immune compromised patients. Early initia- tion of active systemic antifungal therapy is key in improving outcomes. However, early IA diagnosis remains a challenge for physicians.Despite the availability of high-resolution tho- racic computerized tomography (CT) and fungal biomarkers, clinical presentation can be insidious; the clinical and ra- diological spectrum are widely diverse; and diagnostic tests with sufficient sensitivity and specificity are lacking. Additionally, assessing the clinical response of a fungal in- fection remains challenging, in patients with several other clinical conditions. |
| Technique | Analytic |
| Analysis Method | Flow Cytometry Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Flow Cytometry Analysis |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
